Turo Rafal, Smolski Michal, Esler Rachel, Kujawa Magda L, Bromage Stephen J, Oakley Neil, Adeyoju Adebanji, Brown Stephen C W, Brough Richard, Sinclair Andrew, Collins Gerald N
Department of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust , Stockport , UK.
Scand J Urol. 2014 Feb;48(1):4-14. doi: 10.3109/21681805.2013.861508. Epub 2013 Nov 21.
The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.
本综述的目的是讨论己烯雌酚（DES）当前试验的最新数据，以便在新的激素疗法出现时确定其在晚期前列腺癌治疗中的当前作用。从文献中确定了在去势抵抗性前列腺癌（CRPC）中使用DES的最相关临床研究。总结了其安全性、疗效、结果及作用机制。在化疗时代，本综述强调了雌激素疗法在CRPC中的疗效。DES的最佳处方治疗途径仍有待确定。
